{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T00:52:36Z","timestamp":1791075156623,"version":"4.1.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardio-Oncology"],"DOI":"10.1186\/s40959-026-00581-0","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T07:33:50Z","timestamp":1790926430000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term outcomes of prophylactic cardioprotection in early-stage breast cancer patients on non-anthracycline anti-HER2 therapy"],"prefix":"10.1186","volume":"12","author":[{"given":"Thomas Q.","family":"McClelland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikeoluwapo Kendra","family":"Bolakale-Rufai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Zhiying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail S.","family":"Baldridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nausheen","family":"Akhter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,2]]},"reference":[{"issue":"9","key":"581_CR1","doi-asserted-by":"publisher","first-page":"e006915","DOI":"10.1161\/JAHA.117.006915","volume":"6","author":"R Florido","year":"2017","unstructured":"Florido R, Smith KL, Cuomo KK, Russell SD. Cardiotoxicity From Human Epidermal Growth Factor Receptor-2 (HER2) Targeted Therapies. J Am Heart Assoc. 2017;6(9):e006915. https:\/\/doi.org\/10.1161\/JAHA.117.006915.","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"581_CR2","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1097\/HCO.0000000000000637","volume":"34","author":"RS Copeland-Halperin","year":"2019","unstructured":"Copeland-Halperin RS, Liu JE, Yu AF. Cardiotoxicity of HER2-targeted therapies. Curr Opin Cardiol. 2019;34(4):451. https:\/\/doi.org\/10.1097\/HCO.0000000000000637.","journal-title":"Curr Opin Cardiol"},{"issue":"3","key":"581_CR3","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1161\/CIRCHEARTFAILURE.112.000055","volume":"6","author":"S Seicean","year":"2013","unstructured":"Seicean S, Seicean A, Alan N, Plana JC, Budd GT, Marwick TH. Cardioprotective Effect of \u03b2-Adrenoceptor Blockade in Patients With Breast Cancer Undergoing Chemotherapy. Circ Heart Fail. 2013;6(3):420\u20136. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.112.000055.","journal-title":"Circ Heart Fail"},{"issue":"13","key":"581_CR4","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1016\/j.ejca.2013.04.030","volume":"49","author":"K Kalam","year":"2013","unstructured":"Kalam K, Marwick TH. Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: A systematic review and meta-analysis. Eur J Cancer. 2013;49(13):2900\u20139. https:\/\/doi.org\/10.1016\/j.ejca.2013.04.030.","journal-title":"Eur J Cancer"},{"issue":"22","key":"581_CR5","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1016\/j.jacc.2019.03.495","volume":"73","author":"M Guglin","year":"2019","unstructured":"Guglin M, Krischer J, Tamura R, et al. Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer. JACC. 2019;73(22):2859\u201368. https:\/\/doi.org\/10.1016\/j.jacc.2019.03.495.","journal-title":"JACC"},{"issue":"10","key":"581_CR6","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1001\/jamaoncol.2021.3395","volume":"7","author":"L Livi","year":"2021","unstructured":"Livi L, Barletta G, Martella F, et al. Cardioprotective Strategy for Patients With Nonmetastatic Breast Cancer Who Are Receiving an Anthracycline-Based Chemotherapy: A Randomized Clinical Trial. JAMA Oncol. 2021;7(10):1544\u20139. https:\/\/doi.org\/10.1001\/jamaoncol.2021.3395.","journal-title":"JAMA Oncol"},{"issue":"1","key":"581_CR7","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s40959-024-00291-5","volume":"10","author":"FF Gong","year":"2024","unstructured":"Gong FF, Grunblatt E, Voss WB, et al. A strain-guided trial of cardioprotection in early-stage breast cancer patients on anti-HER2 therapy (PROTECT HER2). Cardio-Oncol. 2024;10(1):85. https:\/\/doi.org\/10.1186\/s40959-024-00291-5.","journal-title":"Cardio-Oncol"},{"issue":"23","key":"581_CR8","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1016\/j.jacc.2025.03.546","volume":"85","author":"KF Faridi","year":"2025","unstructured":"Faridi KF, Malik D, Essa M, et al. 10-Year and 30-Year Risks of Cardiovascular Disease in the U.S. Population. J Am Coll Cardiol. 2025;85(23):2239\u201349. https:\/\/doi.org\/10.1016\/j.jacc.2025.03.546.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"581_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaccao.2019.06.004","volume":"1","author":"DP Leong","year":"2019","unstructured":"Leong DP, Cosman T, Alhussein MM, et al. Safety of Continuing Trastuzumab Despite Mild Cardiotoxicity: A Phase I Trial. JACC CardioOncology. 2019;1(1):1\u201310. https:\/\/doi.org\/10.1016\/j.jaccao.2019.06.004.","journal-title":"JACC CardioOncology"},{"issue":"5","key":"581_CR10","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1634\/theoncologist.2016-0412","volume":"22","author":"F Lynce","year":"2017","unstructured":"Lynce F, Barac A, Tan MT, et al. SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2\u2010Positive Breast Cancer and Reduced Left Ventricular Function. Oncologist. 2017;22(5):518\u201325. https:\/\/doi.org\/10.1634\/theoncologist.2016-0412.","journal-title":"Oncologist"},{"issue":"10","key":"581_CR11","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1038\/s41416-020-0786-x","volume":"122","author":"D Eiger","year":"2020","unstructured":"Eiger D, Pond\u00e9 NF, Agbor-Tarh D, et al. Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and\/or trastuzumab Treatment Optimization Trial. Br J Cancer. 2020;122(10):1453\u201360. https:\/\/doi.org\/10.1038\/s41416-020-0786-x.","journal-title":"Br J Cancer"},{"issue":"2","key":"581_CR12","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1406281","volume":"372","author":"SM Tolaney","year":"2015","unstructured":"Tolaney SM, Barry WT, Dang CT, et al. Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer. N Engl J Med. 2015;372(2):134\u201341. https:\/\/doi.org\/10.1056\/NEJMoa1406281.","journal-title":"N Engl J Med"},{"issue":"1","key":"581_CR13","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1001\/jamaoncol.2015.3709","volume":"2","author":"C Dang","year":"2016","unstructured":"Dang C, Guo H, Najita J, et al. Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer. JAMA Oncol. 2016;2(1):29\u201336. https:\/\/doi.org\/10.1001\/jamaoncol.2015.3709.","journal-title":"JAMA Oncol"},{"key":"581_CR14","unstructured":"Rehman M, Cardiotoxicity, and the Evolving Landscape of HER2-Targeted Breast Cancer Treatment. American College of Cardiology. May 24, 2022. Accessed January 10, 2026. https:\/\/www.acc.org\/Latest-in-Cardiology\/Articles\/2022\/05\/23\/13\/25\/http%3a%2f%2fwww.acc.org%2fLatest-in-Cardiology%2fArticles%2f2022%2f05%2f23%2f13%2f25%2fCardiotoxicity-and-the-Evolving-Landscape-of-HER2-Targeted-Breast-Cancer-Treatment."},{"issue":"9","key":"581_CR15","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1136\/heartjnl-2023-323437","volume":"110","author":"C Glen","year":"2024","unstructured":"Glen C, Morrow A, Roditi G, et al. Cardiovascular sequelae of trastuzumab and anthracycline in long-term survivors of breast cancer. Heart. 2024;110(9):650\u20136. https:\/\/doi.org\/10.1136\/heartjnl-2023-323437.","journal-title":"Heart"},{"issue":"1","key":"581_CR16","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jaccao.2022.01.102","volume":"4","author":"H Strongman","year":"2022","unstructured":"Strongman H, Gadd S, Matthews AA, et al. Does Cardiovascular Mortality Overtake Cancer Mortality During Cancer Survivorship? An English Retrospective Cohort Study. JACC CardioOncology. 2022;4(1):113\u201323. https:\/\/doi.org\/10.1016\/j.jaccao.2022.01.102.","journal-title":"JACC CardioOncology"}],"container-title":["Cardio-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-026-00581-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40959-026-00581-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-026-00581-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T00:03:08Z","timestamp":1791072188000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40959-026-00581-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,2]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["581"],"URL":"https:\/\/doi.org\/10.1186\/s40959-026-00581-0","relation":{},"ISSN":["2057-3804"],"issn-type":[{"value":"2057-3804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,2]]},"assertion":[{"value":"28 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Northwestern University IRB approved this study (STU00200675). Consent was waived for the post-hoc analysis but obtained for the PROTECT HER2 cohort.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"119"}}